This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma. Part 1 ...
The Standing National Committee on Medicines (SNCM) for revision of National List of Essential Medicines felt the need for capacity building for pharmacoeconomics as a discipline in India. The same is ...
Highlights from the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting, which took place on May20-24, 2016 in Boston, MA, are available in this ...
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly approved drugs—and often declared them overpriced—companies in the industry ...
Pharmacoeconomics can aid policy makers and healthcare providers in evaluating affordability and access to reasonable drug use, stated Dr Sangita Reddy, immediate past president, FICCI and joint ...
Leerink Center for Pharmacoeconomics highlights societal impact of newly approved schizophrenia drug
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. A Leerink Center for Pharmacoeconomics (CPE) Exclusive ...
China has established itself as a frontrunner in pharmaceutical economics, supported by a network of more than 1,000 specialists advancing medical technology evaluations and regulatory innovations.
As healthcare systems evolve, Pharmacoeconomics will remain a key discipline for guiding decisions that optimize outcomes, resource allocation, and the overall sustainability of healthcare. The MEPDPS ...
Cairo University will introduce an online pharmacoeconomics and health technology assessment diploma programme at the Faculty of Pharmacy as part of the credit-hour system in cooperation with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results